Tryp Therapeutics Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jason Carroll
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1665 Ellis Street Kelowna BC Canada V1Y 2B3
- IPO Date
- Feb 8, 2021
- Website
- tryptherapeutics.com
- Similar Companies
- Business
- Tryptamine Therapeutics Limited, formerly Tryp Therapeutics Inc. (TRYPF), is a clinical-stage biotechnology company focused on developing proprietary formulations of psilocybin and psilocin, the active metabolite of psilocybin, for intravenous infusion and oral administration in combination with psychotherapy to treat neuropsychiatric disorders and chronic pain conditions with high unmet medical needs; its lead product candidate, TRP-8803, comprises a proprietary IV-infused psilocin formulation designed to reduce time to onset, control depth and duration of the psychedelic experience, and shorten overall intervention time compared to oral psilocybin; TRP-8802 is a synthetic oral psilocybin under development; the company also advances TRP-8804 and pursues novel manufacturing techniques and global patents for these psychedelics. TRP-8802 supports ongoing Phase 2a clinical trials for binge eating disorder at the University of Florida, which showed over 80% average reduction in binge episodes, fibromyalgia at the University of Michigan, and planned trials for irritable bowel syndrome-related abdominal pain at Massachusetts General Hospital, with positive results expected to transition to TRP-8803. The company operates in Australia, Canada, Switzerland, and the United States, targeting patients with conditions lacking effective first-line treatments such as eating disorders, fibromyalgia, irritable bowel syndrome, and visceral pain. Founded in 2019 and headquartered in Camberwell, Australia, the company completed a plan of arrangement in May 2024 whereby Exopharm Limited acquired all outstanding shares in an all-stock transaction, resulting in a name change to Tryptamine Therapeutics Limited and listing on the Australian Securities Exchange; recent partnerships include agreements with Albany Molecular Research Inc. for cGMP manufacturing of proprietary psilocybin API and with Alcami for oral formulations.
Tryp Therapeutics Files Amended Financial Statements for the Six Months Ended February 29, 2024
Tryp Therapeutics and Exopharm Limited Announce Completion of Plan of Arrangement
CSE Bulletin: Delist - Tryp Therapeutics Inc. (TRYP)
Tryp Therapeutics Provides Update on Plan of Arrangement With Exopharm Limited and Announces Voluntary Trading Halt
Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order
CSE Bulletin: Reinstatement - Tryp Therapeutics Inc. (TRYP)
Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting
Tryp Therapeutics and Exopharm Limited Secure Pivotal 2 Cent Waiver From ASX
Tryp Therapeutics Announces Significant Milestone in Its Clinical Trial Program for Trp-8803 (IV-infused Psilocin)
Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan
Tryp Therapeutics Inc. Announces Signing of Definitive Agreement with Exopharm Limited
Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3,215,000
Tryp Therapeutics Inc. Announces Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3.0 Million
Tryp Therapeutics Announces Closing of Private Placement of Unsecured Convertible Debentures for Gross Proceeds of AUD$175,000
Tryp Therapeutics Announces Private Placement of Unsecured Convertible Debentures for Gross Proceeds of up to AUD$175,000
Tryp Therapeutics Announces Jason Carroll as New Chief Executive Officer
With Great Sadness Tryp Announces the Passing of David Tousley, Director
Tryp Therapeutics Receives Confirmation From FDA To Proceed With Phase 2A Clinical Trial in Patients With IBS at Massachusetts General Hospital
Tryp Therapeutics to Present at Biotech Showcase on Monday, January 9, 2023
FDA Approves Psilocybin For Binge Eating Study By Tryp Therapeutics